I'm not sure what point you have to continue dismissing me
I'm not sure what point you have to continue dismissing me for some nutto. I believe I already apologized for my over ambitious posts initially. I got excited with the news from KK and presumptuously assumed it was regarding the most recent upcoming meeting, rather than one specifically regarding HIV mono, ideally post BLA submission if remaining on schedule. If I was able to post screenshots of my accounts at Schwab and Fidelity showing my shares owned of Cytodyn and 4 other pharma's, with their respective purchase dates and price points, you would see that I have not sold any shares to date, and have been buying up stock in Cydy sporadically at multiple price points since Feb. 2019 (which was shortly after I was made aware of upcoming meetings...more preliminary in nature). Not only have a not sold a single share of Cydy, the only stocks I've actually sold in the last 6 months was CSCO and INTC, mostly to up my collateral in Cydy and another pharma.
If you don't want to trust what I say that's fine. I only mentioned what I know as a courtesy.
Would you not agree that Cydy Stock price has remained relatively stable? It has been fairly stable no matter if it's doing volume of 100-200k a day or 500-700k. It seems to level itself back towards its baseline. So if I'm right, huge win. If I'm wrong, this will not be a needle mover and will once again stay around baseline. Cytodyn isn't making any wild jumps in share price just because of some news, nor will a hypothetical be a needle mover...until after it's official. If you actually have followed Cydy, you will see what I'm saying is accurate. There is no upside of me being incorrect, it certainly doesn't benefit my shares.
1
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Transforming Fundraising with a Marketplace Twist Sometimes the real treasures are not tucked in textbooks but found in cluttered closets and basements. Enter One Stop Swap with a big idea—they're cooking up a fundraising strategy for schools that could shake things up by helping families sell their unused stuff. It's got that grassroots vibe with the potential to carve...
Continue Reading
Pedaling into a New Era of eBikes When the top contender in the American eBike world rolls out something new, you'd better believe it's worth a look. Lectric eBikes has just unwrapped three limited-edition versions of their beloved XP4, revealing a fresh take on a ride already admired by thousands. Let's dig into this new release. What's New with the XP4 This ain't just a...
Continue Reading
News in the medical world isn't just rattling desks today; it's a purposeful signal for cancer care's transformation. Florida Cancer Specialists & Research Institute (FCS) has beefed up its team, embracing Carlos Barbur, DO, an oncologist who's not just skilled but steeped in disciplines crucial for the health of many. Think of this as another puzzle piece fitting snugly...
Continue Reading
A Bold Move into the U.S. Market MetaOptics Ltd, the semiconductor optics dynamo out of Singapore, is kicking up some investment dust with their American Depositary Receipts (ADR) Programme aimed squarely at expanding its U.S. footprint. And let me tell you, in the game of international market expansion, that's no rookie maneuver. Why ADR? Why Now? So, why is MetaOptics...
Continue Reading
The Thrill of Earnings Season Every trader worth their salt gets a tingle down the spine come earnings season. There's nothing quite like it—the build-up, the anticipation, the potential payouts. This time, we're zeroing in on Target Hospitality, bearing the ticker NASDAQ: TH. Come November 9, 2026, they're set to unveil what the past quarter had up its sleeve, and like...
Continue Reading
Breaking Ground in Prostate Cancer Testing Just when you thought the medical field couldn't shake things up further, Endeavor Health and GoPath Diagnostics swoop in with a new genetic test for prostate cancer. This ain't just any run-of-the-mill test—it's the first of its kind to hit the clinical scene. The focus here is on sorting out which men with prostate cancer are...
Continue Reading
Aviation Dreams Take Off in Nanchang Not every day you see an expo spanning 30,000 square meters focused on aviation, especially where East meets innovation—Nanchang, the beating heart of Jiangxi Province, China, is where it's all happening this time around. October 31, 2026, saw the city launching not rockets but the 2026 Nanchang Aviation Industry Expo, and folks,...
Continue Reading
Walmart's Shelves Get Festive with TAL's New Lineup Alright, so we've got TAL rolling out a limited-edition Holiday Coffee Collection exclusively at Walmart stores. You might wonder why a hydration brand is grabbing headlines right now, but listen up—this stuff just hit on November 2 and it's got the sparkle everyone's eyeing this season. What's Inside this Festive...
Continue Reading
Atrium Therapeutics Strikes a Chord with New Data Tuning into the heartbeats of breakthrough developments, Atrium Therapeutics dropped some fresh, nonclinical insights about their latest contender, ATR 1072. This wasn't just any ordinary announcement; it's like when the market hears whispers of a Fed rate adjustment. The venue? The American Heart Association's 2026...
Continue Reading
Baystate Health Moves Forward with Strategic Integration Well, here's a tale that's as much about legacy as it is about progress. Baystate Health has brought Baystate Mercy Hospital into its fold, blending history with future prospects. This integration, folks, isn't just a merger—it's a downright overhaul of how healthcare operates in Western Massachusetts. We’re...
Continue Reading
Top 5 Most Recently Viewed Articles
Twin Disc's Upcoming Presentation at a Key Conference Twin Disc, Inc. (NASDAQ: TWIN) is gearing up to make a notable appearance at the upcoming Noble Capital Markets Emerging Growth Equity Conference. The event will take place in Boca Raton and is set for a pivotal moment when Chief Financial Officer Jeff Knutson takes the stage to share insights into the company's future...
Continue Reading
Keymed Biosciences Inc. Receives Approval for Stapokibart Keymed Biosciences Inc. (HKEX: 02162) has made impressive advancements in dermatological treatments with the recent marketing approval of Stapokibart. This innovative therapy targets moderate-to-severe atopic dermatitis in adults and has received endorsement from the National Medical Products Administration, the...
Continue Reading
Harnessing AI for Next-Level Value Creation in Tech Firms In today's fast-paced technological landscape, the integration of artificial intelligence (AI) is reshaping the operational dynamics of companies. Innovators are exploring the potential of AI to redefine services, optimize processes, and create new avenues for revenue generation. In a notable address, an industry...
Continue Reading
CoinShares Executes Employee Share Options with Success CoinShares International Limited (Nasdaq Stockholm Market: CS; US OTCQX: CNSRF) has made a significant announcement regarding its Employee Incentive Plan. Recently, the firm revealed that it has successfully exercised a total of 25,000 options from its Employee Incentive Plan - November 2020 Tranche. This is an...
Continue Reading
EverQuote Reports Strong Growth in Q3 2025 EverQuote, Inc. (Nasdaq: EVER), a prominent player in the online insurance marketplace, has revealed impressive financial results for the third quarter of 2025, showing significant growth across several critical metrics. Revenue surged by 20% year-over-year, reaching $173.9 million, reflecting the company's effective strategies...
Continue Reading